Industry Information

Update July 13, 2021

Review of the first half of 2021: Hotview Biotech's growth rate is the first, and medical equipment welcomes IPO financing

In the first half of 2021, due to the impact of the new crown epidemic in some regions, pharmaceutical companies such as medical devices and biological vaccines have been favored by the capital...

Update July 12, 2021

[Yao Ka Jun] 27 new drugs have been approved for clinical use, and “first-in-class” new drugs are still mainly introduced, BeiGene, Kelun, Zai Lab...

Yaozhi data shows that in this period (July 2 to July 9), 27 new drugs were approved clinically (40 acceptance numbers); another 39 varieties (60 acceptance numbers) clinical applications were...

Update July 10, 2021

Cinda Biotech's first small molecule anti-cancer drug, pemigatinib, has been declared for the market !

July 9, 2021, San Francisco, USA and Suzhou, China-Cinda Biopharmaceuticals (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of...

Update July 09, 2021

Dry goods! Analysis report of CDE drug review in the first half of 2021

一. In the first half of 2021, the overall situation of drug registration applications 1. Application status of each drug type In 2021, CDE has undertaken a total of 5,155 new drug registration...

Update July 08, 2021

The tragedy of Chinese innovative drugs? First in class has not yet sprouted, but "pseudo-innovation" has become a target of severe crackdown...

On July 2, the Drug Evaluation Center of the National Medical Products Administration issued a notice for publicly soliciting opinions on the "Clinical Value-Oriented Anti-tumor Drug Clinical...

Update July 07, 2021

White horse stumbles! The listing of 8 innovative drugs still plummeted, what happened to Hengrui?

On July 2, 2021, the Center for Drug Evaluation (CDE) of the National Medical Products Administration issued the "Guiding Principles for Clinical Research and Development of Antitumor Drugs Oriented...

Update July 06, 2021

Looking at the development of Chinese medicine from the reform of the patent system

Patent right is an intangible property right, and the essence of the patent system is to protect innovation. With the evolution of the international and domestic economic situation, my country's...

Update July 05, 2021

The first imitation in China! United Laboratories' "Somaglutide" clinical trial application accepted

On June 29, 2021, Zhuhai United Laboratories Co., Ltd. announced that it had received the Notice of Acceptance of Clinical Registration Application for Semaglutide Injection (Semaglutide Injection)...

Update July 02, 2021

First-line treatment of squamous non-small cell lung cancer! Kangfang Bio-PD-1 monoclonal antibody submitted a new indication for marketing application

On July 2, 2021, Kangfang Bio-Bio announced that the PD-1 monoclonal antibody drug Paimrizumab (R&D code: AK105, trade name) jointly developed by the company and China Biopharmaceutical Co., Ltd....

Update July 01, 2021

"Drugs" become "luxuries", performance growth depends on price increases, is Pien Tze Huang still fragrant?

Recently, the national first-class confidential Chinese medicine Pill Zihuang's value has skyrocketed, with an ex-factory price of 590 yuan. E-commerce platforms generally cost more than 1,000 yuan...